Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine

Background: Irritable bowel syndrome (IBS) is a functional gastrointestinal condition marked by chronic bowel pain or discomfort, as well as changes in abdominal motility. Despite its worldwide prevalence and clinical impact, the cause of IBS is unknown. Inflammation could play a fundamental role in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sahar M. El‑Haggar, Sahar K. Hegazy, Sherief M. Abd-Elsalam, Mostafa M. Bahaa
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2022
Materias:	Phosphodiesterase inhibitors IBS Pentoxifylline Inflammation Visceral Hypersensitivity Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/4ee74657a09b4c18aa2c8a8fc9d5b97d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4ee74657a09b4c18aa2c8a8fc9d5b97d
record_format	dspace
spelling	oai:doaj.org-article:4ee74657a09b4c18aa2c8a8fc9d5b97d2021-11-14T04:30:29ZPentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine0753-332210.1016/j.biopha.2021.112399https://doaj.org/article/4ee74657a09b4c18aa2c8a8fc9d5b97d2022-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S0753332221011859https://doaj.org/toc/0753-3322Background: Irritable bowel syndrome (IBS) is a functional gastrointestinal condition marked by chronic bowel pain or discomfort, as well as changes in abdominal motility. Despite its worldwide prevalence and clinical impact, the cause of IBS is unknown. Inflammation could play a fundamental role in the development of IBS. The aim of this study was to examine whether pentoxifylline, a competitive nonselective phosphodiesterase inhibitor, is useful in alleviating abdominal pain in IBS patients treated with mebeverine. Methods: A randomized, controlled, and prospective clinical study that included 50 outpatients who met the inclusion criteria for IBS. Patients are allocated randomly into two groups (n = 25). Group 1 (mebeverine group) received mebeverine 135 mg three times daily (t.i.d) for three months. Group 2 (pentoxifylline group) received mebeverine 135 mg t.i.d and pentoxifylline 400 mg two times daily for three months. Patients were assessed by a gastroenterologist at baseline and three months after the medication had been started. The serum levels of interleukin-6, interleukin-8 and tumor necrosis factor-alpha, fecal Neutrophil Gelatinase Associated Lipocalin (NGAL), and fecal myeloperoxidase were measured at the start and after three months of therapy. The Numeric Pain Rating scale (NRS) was assessed at baseline and after therapy. Results: the pentoxifylline group showed a significant decrease in the level of measured biomarkers and a significant decrease in NRS. Conclusion: Pentoxifylline could be a promising adjuvant anti-inflammatory drug in the treatment of abdominal pain in IBS patients treated with mebeverine.Sahar M. El‑HaggarSahar K. HegazySherief M. Abd-ElsalamMostafa M. BahaaElsevierarticlePhosphodiesterase inhibitorsIBSPentoxifyllineInflammationVisceral HypersensitivityTherapeutics. PharmacologyRM1-950ENBiomedicine & Pharmacotherapy, Vol 145, Iss , Pp 112399- (2022)
institution	DOAJ
collection	DOAJ
language	EN
topic	Phosphodiesterase inhibitors IBS Pentoxifylline Inflammation Visceral Hypersensitivity Therapeutics. Pharmacology RM1-950
spellingShingle	Phosphodiesterase inhibitors IBS Pentoxifylline Inflammation Visceral Hypersensitivity Therapeutics. Pharmacology RM1-950 Sahar M. El‑Haggar Sahar K. Hegazy Sherief M. Abd-Elsalam Mostafa M. Bahaa Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine
description	Background: Irritable bowel syndrome (IBS) is a functional gastrointestinal condition marked by chronic bowel pain or discomfort, as well as changes in abdominal motility. Despite its worldwide prevalence and clinical impact, the cause of IBS is unknown. Inflammation could play a fundamental role in the development of IBS. The aim of this study was to examine whether pentoxifylline, a competitive nonselective phosphodiesterase inhibitor, is useful in alleviating abdominal pain in IBS patients treated with mebeverine. Methods: A randomized, controlled, and prospective clinical study that included 50 outpatients who met the inclusion criteria for IBS. Patients are allocated randomly into two groups (n = 25). Group 1 (mebeverine group) received mebeverine 135 mg three times daily (t.i.d) for three months. Group 2 (pentoxifylline group) received mebeverine 135 mg t.i.d and pentoxifylline 400 mg two times daily for three months. Patients were assessed by a gastroenterologist at baseline and three months after the medication had been started. The serum levels of interleukin-6, interleukin-8 and tumor necrosis factor-alpha, fecal Neutrophil Gelatinase Associated Lipocalin (NGAL), and fecal myeloperoxidase were measured at the start and after three months of therapy. The Numeric Pain Rating scale (NRS) was assessed at baseline and after therapy. Results: the pentoxifylline group showed a significant decrease in the level of measured biomarkers and a significant decrease in NRS. Conclusion: Pentoxifylline could be a promising adjuvant anti-inflammatory drug in the treatment of abdominal pain in IBS patients treated with mebeverine.
format	article
author	Sahar M. El‑Haggar Sahar K. Hegazy Sherief M. Abd-Elsalam Mostafa M. Bahaa
author_facet	Sahar M. El‑Haggar Sahar K. Hegazy Sherief M. Abd-Elsalam Mostafa M. Bahaa
author_sort	Sahar M. El‑Haggar
title	Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine
title_short	Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine
title_full	Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine
title_fullStr	Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine
title_full_unstemmed	Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine
title_sort	pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine
publisher	Elsevier
publishDate	2022
url	https://doaj.org/article/4ee74657a09b4c18aa2c8a8fc9d5b97d
work_keys_str_mv	AT saharmelhaggar pentoxifyllineanonselectivephosphodiesteraseinhibitorinadjunctivetherapyinpatientswithirritablebowelsyndrometreatedwithmebeverine AT saharkhegazy pentoxifyllineanonselectivephosphodiesteraseinhibitorinadjunctivetherapyinpatientswithirritablebowelsyndrometreatedwithmebeverine AT sheriefmabdelsalam pentoxifyllineanonselectivephosphodiesteraseinhibitorinadjunctivetherapyinpatientswithirritablebowelsyndrometreatedwithmebeverine AT mostafambahaa pentoxifyllineanonselectivephosphodiesteraseinhibitorinadjunctivetherapyinpatientswithirritablebowelsyndrometreatedwithmebeverine
_version_	1718429955540385792

Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine

Ejemplares similares